Global and China Fibromyalgia Therapeutics Market Size, Status and Forecast 2020-2026

September 2020 | 131 pages | ID: G10474A4ECF8EN
QYResearch

Abstracts

Global Fibromyalgia Therapeutics Scope and Market Size
Fibromyalgia Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Fibromyalgia Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.
Market segment by Type, the product can be split into

• Cymbalta (Duloxetine)
• Savella (Milnacipran)
• Lyrica (Pregabalin)
• Pancuronium
• Others

Market segment by Application, split into

• Hospital
• Clinic
• Others

Based on regional and country-level analysis, the Fibromyalgia Therapeutics market has been segmented as follows:

• North America
• United States
• Canada
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic
• Rest of Europe
• Asia-Pacific
• China
• Japan
• South Korea
• Southeast Asia
• India
• Australia
• Rest of Asia-Pacific
• Latin America
• Mexico
• Brazil
• Middle East & Africa
• Turkey
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

In the competitive analysis section of the report, leading as well as prominent players of the global Fibromyalgia Therapeutics market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.
The key players covered in this study

• Pfizer
• Eli Lilly
• Actavis
• Merck Sharp and Dohme
• Daiichi Sankyo
• Innovative Med Concepts
• Meda
• Meiji Seika
• Switch Biotech
• Theravance
• Zynerba Pharmaceuticals
• Tonix Pharmaceuticals Holding Corp. (TNXP)
• Daiichi Sankyo
• Forest Pharmaceuticals, Inc.
• Boehringer Ingelheim GmbH
• Pierre Fabre Mdicament

Contents

1 REPORT OVERVIEW

1.1 Study Scope
1.2 Market Analysis by Type
  1.2.1 Global Fibromyalgia Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
  1.2.2 Cymbalta (Duloxetine)
  1.2.3 Savella (Milnacipran)
  1.2.4 Lyrica (Pregabalin)
  1.2.5 Pancuronium
  1.2.6 Others
1.3 Market by Application
  1.3.1 Global Fibromyalgia Therapeutics Market Share by Application: 2020 VS 2026
  1.3.2 Hospital
  1.3.3 Clinic
  1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 GLOBAL GROWTH TRENDS

2.1 Global Fibromyalgia Therapeutics Market Perspective (2015-2026)
2.2 Global Fibromyalgia Therapeutics Growth Trends by Regions
  2.2.1 Fibromyalgia Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
  2.2.2 Fibromyalgia Therapeutics Historic Market Share by Regions (2015-2020)
  2.2.3 Fibromyalgia Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
  2.3.1 Market Trends
  2.3.2 Market Drivers
  2.3.3 Market Challenges
  2.3.4 Market Restraints

3 COMPETITION LANDSCAPE BY KEY PLAYERS

3.1 Global Top Fibromyalgia Therapeutics Players by Market Size
  3.1.1 Global Top Fibromyalgia Therapeutics Players by Revenue (2015-2020)
  3.1.2 Global Fibromyalgia Therapeutics Revenue Market Share by Players (2015-2020)
3.2 Global Fibromyalgia Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Fibromyalgia Therapeutics Revenue
3.4 Global Fibromyalgia Therapeutics Market Concentration Ratio
  3.4.1 Global Fibromyalgia Therapeutics Market Concentration Ratio (CR5 and HHI)
  3.4.2 Global Top 10 and Top 5 Companies by Fibromyalgia Therapeutics Revenue in 2019
3.5 Key Players Fibromyalgia Therapeutics Area Served
3.6 Key Players Fibromyalgia Therapeutics Product Solution and Service
3.7 Date of Enter into Fibromyalgia Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 FIBROMYALGIA THERAPEUTICS BREAKDOWN DATA BY TYPE (2015-2026)

4.1 Global Fibromyalgia Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Fibromyalgia Therapeutics Forecasted Market Size by Type (2021-2026)

5 FIBROMYALGIA THERAPEUTICS BREAKDOWN DATA BY APPLICATION (2015-2026)

5.1 Global Fibromyalgia Therapeutics Historic Market Size by Application (2015-2020)
5.2 Global Fibromyalgia Therapeutics Forecasted Market Size by Application (2021-2026)

6 NORTH AMERICA

6.1 North America Fibromyalgia Therapeutics Market Size (2015-2026)
6.2 North America Fibromyalgia Therapeutics Market Size by Type (2015-2020)
6.3 North America Fibromyalgia Therapeutics Market Size by Application (2015-2020)
6.4 North America Fibromyalgia Therapeutics Market Size by Country (2015-2020)
  6.4.1 United States
  6.4.2 Canada

7 EUROPE

7.1 Europe Fibromyalgia Therapeutics Market Size (2015-2026)
7.2 Europe Fibromyalgia Therapeutics Market Size by Type (2015-2020)
7.3 Europe Fibromyalgia Therapeutics Market Size by Application (2015-2020)
7.4 Europe Fibromyalgia Therapeutics Market Size by Country (2015-2020)
  7.4.1 Germany
  7.4.2 France
  7.4.3 U.K.
  7.4.4 Italy
  7.4.5 Russia
  7.4.6 Nordic
  7.4.7 Rest of Europe

8 CHINA

8.1 China Fibromyalgia Therapeutics Market Size (2015-2026)
8.2 China Fibromyalgia Therapeutics Market Size by Type (2015-2020)
8.3 China Fibromyalgia Therapeutics Market Size by Application (2015-2020)
8.4 China Fibromyalgia Therapeutics Market Size by Region (2015-2020)
  8.4.1 China
  8.4.2 Japan
  8.4.3 South Korea
  8.4.4 Southeast Asia
  8.4.5 India
  8.4.6 Australia
  8.4.7 Rest of Asia-Pacific

9 JAPAN

9.1 Japan Fibromyalgia Therapeutics Market Size (2015-2026)
9.2 Japan Fibromyalgia Therapeutics Market Size by Type (2015-2020)
9.3 Japan Fibromyalgia Therapeutics Market Size by Application (2015-2020)
9.4 Japan Fibromyalgia Therapeutics Market Size by Country (2015-2020)
  9.4.1 Mexico
  9.4.2 Brazil

10 SOUTHEAST ASIA

10.1 Southeast Asia Fibromyalgia Therapeutics Market Size (2015-2026)
10.2 Southeast Asia Fibromyalgia Therapeutics Market Size by Type (2015-2020)
10.3 Southeast Asia Fibromyalgia Therapeutics Market Size by Application (2015-2020)
10.4 Southeast Asia Fibromyalgia Therapeutics Market Size by Country (2015-2020)
  10.4.1 Turkey
  10.4.2 Saudi Arabia
  10.4.3 UAE
  10.4.4 Rest of Middle East & Africa

11KEY PLAYERS PROFILES

11.1 Pfizer
  11.1.1 Pfizer Company Details
  11.1.2 Pfizer Business Overview
  11.1.3 Pfizer Fibromyalgia Therapeutics Introduction
  11.1.4 Pfizer Revenue in Fibromyalgia Therapeutics Business (2015-2020))
  11.1.5 Pfizer Recent Development
11.2 Eli Lilly
  11.2.1 Eli Lilly Company Details
  11.2.2 Eli Lilly Business Overview
  11.2.3 Eli Lilly Fibromyalgia Therapeutics Introduction
  11.2.4 Eli Lilly Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  11.2.5 Eli Lilly Recent Development
11.3 Actavis
  11.3.1 Actavis Company Details
  11.3.2 Actavis Business Overview
  11.3.3 Actavis Fibromyalgia Therapeutics Introduction
  11.3.4 Actavis Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  11.3.5 Actavis Recent Development
11.4 Merck Sharp and Dohme
  11.4.1 Merck Sharp and Dohme Company Details
  11.4.2 Merck Sharp and Dohme Business Overview
  11.4.3 Merck Sharp and Dohme Fibromyalgia Therapeutics Introduction
  11.4.4 Merck Sharp and Dohme Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  11.4.5 Merck Sharp and Dohme Recent Development
11.5 Daiichi Sankyo
  11.5.1 Daiichi Sankyo Company Details
  11.5.2 Daiichi Sankyo Business Overview
  11.5.3 Daiichi Sankyo Fibromyalgia Therapeutics Introduction
  11.5.4 Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  11.5.5 Daiichi Sankyo Recent Development
11.6 Innovative Med Concepts
  11.6.1 Innovative Med Concepts Company Details
  11.6.2 Innovative Med Concepts Business Overview
  11.6.3 Innovative Med Concepts Fibromyalgia Therapeutics Introduction
  11.6.4 Innovative Med Concepts Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  11.6.5 Innovative Med Concepts Recent Development
11.7 Meda
  11.7.1 Meda Company Details
  11.7.2 Meda Business Overview
  11.7.3 Meda Fibromyalgia Therapeutics Introduction
  11.7.4 Meda Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  11.7.5 Meda Recent Development
11.8 Meiji Seika
  11.8.1 Meiji Seika Company Details
  11.8.2 Meiji Seika Business Overview
  11.8.3 Meiji Seika Fibromyalgia Therapeutics Introduction
  11.8.4 Meiji Seika Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  11.8.5 Meiji Seika Recent Development
11.9 Switch Biotech
  11.9.1 Switch Biotech Company Details
  11.9.2 Switch Biotech Business Overview
  11.9.3 Switch Biotech Fibromyalgia Therapeutics Introduction
  11.9.4 Switch Biotech Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  11.9.5 Switch Biotech Recent Development
11.10 Theravance
  11.10.1 Theravance Company Details
  11.10.2 Theravance Business Overview
  11.10.3 Theravance Fibromyalgia Therapeutics Introduction
  11.10.4 Theravance Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  11.10.5 Theravance Recent Development
11.11 Zynerba Pharmaceuticals
  10.11.1 Zynerba Pharmaceuticals Company Details
  10.11.2 Zynerba Pharmaceuticals Business Overview
  10.11.3 Zynerba Pharmaceuticals Fibromyalgia Therapeutics Introduction
  10.11.4 Zynerba Pharmaceuticals Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  10.11.5 Zynerba Pharmaceuticals Recent Development
11.12 Tonix Pharmaceuticals Holding Corp. (TNXP)
  10.12.1 Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
  10.12.2 Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
  10.12.3 Tonix Pharmaceuticals Holding Corp. (TNXP) Fibromyalgia Therapeutics Introduction
  10.12.4 Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  10.12.5 Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
11.13 Daiichi Sankyo
  10.13.1 Daiichi Sankyo Company Details
  10.13.2 Daiichi Sankyo Business Overview
  10.13.3 Daiichi Sankyo Fibromyalgia Therapeutics Introduction
  10.13.4 Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  10.13.5 Daiichi Sankyo Recent Development
11.14 Forest Pharmaceuticals, Inc.
  10.14.1 Forest Pharmaceuticals, Inc. Company Details
  10.14.2 Forest Pharmaceuticals, Inc. Business Overview
  10.14.3 Forest Pharmaceuticals, Inc. Fibromyalgia Therapeutics Introduction
  10.14.4 Forest Pharmaceuticals, Inc. Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  10.14.5 Forest Pharmaceuticals, Inc. Recent Development
11.15 Boehringer Ingelheim GmbH
  10.15.1 Boehringer Ingelheim GmbH Company Details
  10.15.2 Boehringer Ingelheim GmbH Business Overview
  10.15.3 Boehringer Ingelheim GmbH Fibromyalgia Therapeutics Introduction
  10.15.4 Boehringer Ingelheim GmbH Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  10.15.5 Boehringer Ingelheim GmbH Recent Development
11.16 Pierre Fabre Mdicament
  10.16.1 Pierre Fabre Mdicament Company Details
  10.16.2 Pierre Fabre Mdicament Business Overview
  10.16.3 Pierre Fabre Mdicament Fibromyalgia Therapeutics Introduction
  10.16.4 Pierre Fabre Mdicament Revenue in Fibromyalgia Therapeutics Business (2015-2020)
  10.16.5 Pierre Fabre Mdicament Recent Development

12ANALYST'S VIEWPOINTS/CONCLUSIONS

13APPENDIX

13.1 Research Methodology
  13.1.1 Methodology/Research Approach
  13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List Of Tables

LIST OF TABLES

Table 1. Global Fibromyalgia Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 3. Key Players of Cymbalta (Duloxetine)
Table 4. Key Players of Savella (Milnacipran)
Table 5. Key Players of Lyrica (Pregabalin)
Table 6. Key Players of Pancuronium
Table 7. Key Players of Others
Table 8. Global Fibromyalgia Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 9. Global Fibromyalgia Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 10. Global Fibromyalgia Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 11. Global Fibromyalgia Therapeutics Market Share by Regions (2015-2020)
Table 12. Global Fibromyalgia Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 13. Global Fibromyalgia Therapeutics Market Share by Regions (2021-2026)
Table 14. Fibromyalgia Therapeutics Market Market Trends
Table 15. Fibromyalgia Therapeutics Market Drivers
Table 16. Fibromyalgia Therapeutics Market Challenges
Table 17. Fibromyalgia Therapeutics Market Restraints
Table 18. Global Fibromyalgia Therapeutics Revenue by Players (2015-2020) (US$ Million)
Table 19. Global Fibromyalgia Therapeutics Market Share by Players (2015-2020)
Table 20. Global Top Fibromyalgia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fibromyalgia Therapeutics as of 2019)
Table 21. Global Fibromyalgia Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Fibromyalgia Therapeutics Product Solution and Service
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Fibromyalgia Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 26. Global Fibromyalgia Therapeutics Market Size Share by Type (2015-2020)
Table 27. Global Fibromyalgia Therapeutics Revenue Market Share by Type (2021-2026)
Table 28. Global Fibromyalgia Therapeutics Market Size Share by Application (2015-2020)
Table 29. Global Fibromyalgia Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 30. Global Fibromyalgia Therapeutics Market Size Share by Application (2021-2026)
Table 31. North America Fibromyalgia Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 32. North America Fibromyalgia Therapeutics Market Share by Type (2015-2020)
Table 33. North America Fibromyalgia Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 34. North America Fibromyalgia Therapeutics Market Share by Application (2015-2020)
Table 35. North America Fibromyalgia Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 36. North America Fibromyalgia Therapeutics Market Share by Country (2015-2020)
Table 37. Europe Fibromyalgia Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 38. Europe Fibromyalgia Therapeutics Market Share by Type (2015-2020)
Table 39. Europe Fibromyalgia Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 40. Europe Fibromyalgia Therapeutics Market Share by Application (2015-2020)
Table 41. Europe Fibromyalgia Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 42. Europe Fibromyalgia Therapeutics Market Share by Country (2015-2020)
Table 43. China Fibromyalgia Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 44. China Fibromyalgia Therapeutics Market Share by Type (2015-2020)
Table 45. China Fibromyalgia Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 46. China Fibromyalgia Therapeutics Market Share by Application (2015-2020)
Table 47. China Fibromyalgia Therapeutics Market Size by Region (US$ Million) (2015-2020)
Table 48. China Fibromyalgia Therapeutics Market Share by Region (2015-2020)
Table 49. Japan Fibromyalgia Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 50. Japan Fibromyalgia Therapeutics Market Share by Type (2015-2020)
Table 51. Japan Fibromyalgia Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 52. Japan Fibromyalgia Therapeutics Market Share by Application (2015-2020)
Table 53. Japan Fibromyalgia Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 54. Japan Fibromyalgia Therapeutics Market Share by Country (2015-2020)
Table 55. Southeast Asia Fibromyalgia Therapeutics Market Size by Type (2015-2020) (US$ Million)
Table 56. Southeast Asia Fibromyalgia Therapeutics Market Share by Type (2015-2020)
Table 57. Southeast Asia Fibromyalgia Therapeutics Market Size by Application (2015-2020) (US$ Million)
Table 58. Southeast Asia Fibromyalgia Therapeutics Market Share by Application (2015-2020)
Table 59. Southeast Asia Fibromyalgia Therapeutics Market Size by Country (US$ Million) (2015-2020)
Table 60. Southeast Asia Fibromyalgia Therapeutics Market Share by Country (2015-2020)
Table 61. Pfizer Company Details
Table 62. Pfizer Business Overview
Table 63. Pfizer Product
Table 64. Pfizer Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 65. Pfizer Recent Development
Table 66. Eli Lilly Company Details
Table 67. Eli Lilly Business Overview
Table 68. Eli Lilly Product
Table 69. Eli Lilly Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 70. Eli Lilly Recent Development
Table 71. Actavis Company Details
Table 72. Actavis Business Overview
Table 73. Actavis Product
Table 74. Actavis Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 75. Actavis Recent Development
Table 76. Merck Sharp and Dohme Company Details
Table 77. Merck Sharp and Dohme Business Overview
Table 78. Merck Sharp and Dohme Product
Table 79. Merck Sharp and Dohme Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 80. Merck Sharp and Dohme Recent Development
Table 81. Daiichi Sankyo Company Details
Table 82. Daiichi Sankyo Business Overview
Table 83. Daiichi Sankyo Product
Table 84. Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 85. Daiichi Sankyo Recent Development
Table 86. Innovative Med Concepts Company Details
Table 87. Innovative Med Concepts Business Overview
Table 88. Innovative Med Concepts Product
Table 89. Innovative Med Concepts Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 90. Innovative Med Concepts Recent Development
Table 91. Meda Company Details
Table 92. Meda Business Overview
Table 93. Meda Product
Table 94. Meda Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 95. Meda Recent Development
Table 96. Meiji Seika Business Overview
Table 97. Meiji Seika Product
Table 98. Meiji Seika Company Details
Table 99. Meiji Seika Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 100. Meiji Seika Recent Development
Table 101. Switch Biotech Company Details
Table 102. Switch Biotech Business Overview
Table 103. Switch Biotech Product
Table 104. Switch Biotech Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 105. Switch Biotech Recent Development
Table 106. Theravance Company Details
Table 107. Theravance Business Overview
Table 108. Theravance Product
Table 109. Theravance Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 110. Theravance Recent Development
Table 111. Zynerba Pharmaceuticals Company Details
Table 112. Zynerba Pharmaceuticals Business Overview
Table 113. Zynerba Pharmaceuticals Product
Table 114. Zynerba Pharmaceuticals Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 115. Zynerba Pharmaceuticals Recent Development
Table 116. Tonix Pharmaceuticals Holding Corp. (TNXP) Company Details
Table 117. Tonix Pharmaceuticals Holding Corp. (TNXP) Business Overview
Table 118. Tonix Pharmaceuticals Holding Corp. (TNXP) Product
Table 119. Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 120. Tonix Pharmaceuticals Holding Corp. (TNXP) Recent Development
Table 121. Daiichi Sankyo Company Details
Table 122. Daiichi Sankyo Business Overview
Table 123. Daiichi Sankyo Product
Table 124. Daiichi Sankyo Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 125. Daiichi Sankyo Recent Development
Table 126. Forest Pharmaceuticals, Inc. Company Details
Table 127. Forest Pharmaceuticals, Inc. Business Overview
Table 128. Forest Pharmaceuticals, Inc. Product
Table 129. Forest Pharmaceuticals, Inc. Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 130. Forest Pharmaceuticals, Inc. Recent Development
Table 131. Boehringer Ingelheim GmbH Company Details
Table 132. Boehringer Ingelheim GmbH Business Overview
Table 133. Boehringer Ingelheim GmbH Product
Table 134. Boehringer Ingelheim GmbH Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 135. Boehringer Ingelheim GmbH Recent Development
Table 136. Pierre Fabre Mdicament Company Details
Table 137. Pierre Fabre Mdicament Business Overview
Table 138. Pierre Fabre Mdicament Product
Table 139. Pierre Fabre Mdicament Revenue in Fibromyalgia Therapeutics Business (2015-2020) (US$ Million)
Table 140. Pierre Fabre Mdicament Recent Development
Table 141. Research Programs/Design for This Report
Table 142. Key Data Information from Secondary Sources
Table 143. Key Data Information from Primary Sources

List Of Figures

LIST OF FIGURES

Figure 1. Global Fibromyalgia Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Cymbalta (Duloxetine) Features
Figure 3. Savella (Milnacipran) Features
Figure 4. Lyrica (Pregabalin) Features
Figure 5. Pancuronium Features
Figure 6. Others Features
Figure 7. Global Fibromyalgia Therapeutics Market Share by Application: 2020 VS 2026
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Fibromyalgia Therapeutics Report Years Considered
Figure 12. Global Fibromyalgia Therapeutics Market Size (US$ Million), YoY Growth 2015-2026
Figure 13. Global Fibromyalgia Therapeutics Market Share by Regions: 2020 VS 2026
Figure 14. Global Fibromyalgia Therapeutics Market Share by Regions (2021-2026)
Figure 15. Global Fibromyalgia Therapeutics Market Share by Players in 2019
Figure 16. Global Top Fibromyalgia Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Fibromyalgia Therapeutics as of 2019
Figure 17. The Top 10 and 5 Players Market Share by Fibromyalgia Therapeutics Revenue in 2019
Figure 18. North America Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 19. United States Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 20. Canada Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 21. Europe Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 22. Germany Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 23. France Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 24. U.K. Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 25. Italy Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 26. Russia Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 27. Nordic Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 28. Rest of Europe Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 29. Asia-Pacific Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 30. China Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 31. Japan Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 32. South Korea Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 33. Southeast Asia Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 34. India Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 35. Australia Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 36. Rest of Asia-Pacific Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 37. Latin America Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 38. Mexico Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 39. Brazil Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 40. Middle East & Africa Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 41. Turkey Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 42. Saudi Arabia Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 43. UAE Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 44. Rest of Middle East & Africa Fibromyalgia Therapeutics Market Size YoY Growth (2015-2026) & (US$ Million)
Figure 45. Pfizer Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 46. Eli Lilly Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 47. Actavis Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 48. Merck Sharp and Dohme Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 49. Daiichi Sankyo Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 50. Innovative Med Concepts Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 51. Meda Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 52. Meiji Seika Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 53. Switch Biotech Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 54. Theravance Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 55. Zynerba Pharmaceuticals Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 56. Tonix Pharmaceuticals Holding Corp. (TNXP) Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 57. Daiichi Sankyo Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 58. Forest Pharmaceuticals, Inc. Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 59. Boehringer Ingelheim GmbH Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 60. Pierre Fabre Mdicament Revenue Growth Rate in Fibromyalgia Therapeutics Business (2015-2020)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed